Affiris Ag

Ac Immune Sa

Affiris Cvd Gmbh

Gergana Galabova

Guenther Staffler

Sylvia Brunner

Claudia Juno

Gabriele Winsauer

Birgit Schuh

Erika Bilcikova

Pola Linzmayer-Hirt

Bettina Wanko

Markus Windwarder

Gunther Staffler

Achim Schneeberger

Arne Von Bonin

Andreas Mairhofer

Dorian Winter

Jana Zimmermann

Günther Staffler

Sabine Schmidhuber

Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.

Method for vaccination against a self-antigen in a human patient

The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Peptide vaccines for hypercholesterolemia related diseases

Peptide vaccines usable for hypercholesterolemia related diseases

The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Peptide vaccines against PCSK9

Treatments using a peptide and/or vaccine

The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).

PCSK9 peptide combination vaccine and method of use

Vaccine capable of inducing formation of antibodies directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) in vivo

A vaccine or immunogenic composition comprising at least two fragments of proprotein convertase subtilisin/kexin type 9 (PCSK9) where one fragment contains at least 9 consecutive residues of residues 153 to 165 of PCSK9 and the other fragment contains at least 9 consecutive residues 209 to 222 of the PCSK9 (SEQ ID NO:9). Methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis involving administering this vaccine.

Growing community of inventors

Vienna, Austria

Gergana Galabova